Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy

Next Previous
Trial Profile

A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doravirine/islatravir (Primary) ; Abacavir; Abacavir/dolutegravir/lamivudine; Atazanavir; Atazanavir/cobicistat; Bictegravir/emtricitabine/tenofovir alafenamide; Cobicistat; Cobicistat/darunavir; Cobicistat/darunavir/emtricitabine/tenofovir alafenamide; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Darunavir; Dolutegravir; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Emtricitabine; Emtricitabine/rilpivirine/tenofovir alafenamide; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir alafenamide; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Lamivudine; Lamivudine/abacavir; Lopinavir/ritonavir; Nevirapine; Raltegravir; Rilpivirine; Ritonavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ILLUMINATE SWITCH A
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 01 Sep 2024 This trial has been completed in France (End date: 2024-08-19) according to European Clinical Trials Database record.
  • 26 Mar 2024 Planned End Date changed from 30 Mar 2024 to 22 Nov 2024.
  • 22 Feb 2023 Results of week 48 evaluating a switch from oral combination ART to DOR/ISL (100/0.75mg), a once-daily single-tablet regimen, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top